Should You Continue to Hold Charles River Stock in Your Portfolio?

Charles River Laboratories International, Inc. (CRL) expands its products and services across the drug discovery and early-stage development continuum through targeted partnerships and acquisitions. The company’s Research Models and Services (RMS) segment is gaining from strong revenues of small research models. Signs of stabilization and improved bookings in the Discovery and Safety Assessment (DSA) segment are encouraging. Yet, the adverse macroeconomic impacts and currency woes pose risks for the company ...